Core Viewpoint - Kymera Therapeutics, Inc. has successfully closed an upsized underwritten public offering, raising $602.0 million through the sale of 8,050,000 shares of common stock at a price of $86.00 per share, resulting in gross proceeds of approximately $692.3 million before expenses [1][2]. Company Overview - Kymera Therapeutics is a clinical-stage biotechnology company focused on developing targeted protein degradation (TPD) therapies for immunological diseases, aiming to create a new generation of oral small molecule degrader medicines [6]. - The company has advanced its first degrader into clinical trials and is committed to building a robust pipeline of innovative therapies that address critical health issues [6]. - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces in recent years [6]. Offering Details - The public offering was managed by a consortium of financial institutions including Morgan Stanley, J.P. Morgan, Jefferies, Stifel, Guggenheim Securities, and Wells Fargo Securities [2]. - The offering was conducted under an automatically effective shelf registration statement filed with the SEC on October 31, 2024 [3]. - A final prospectus supplement detailing the terms of the offering has been filed with the SEC and is available for public access [4].

Core Insights - Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases [1][3] - The company will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference on May 14, 2025 [1] - A live webcast of the presentation will be available on the company's website, with a replay archived post-event [2] Company Overview - Kymera Therapeutics is pioneering targeted protein degradation (TPD) to create medicines for critical health issues, aiming to improve patient outcomes significantly [3] - The company has advanced its first degrader into clinical trials for immunological diseases and is building a robust pipeline of oral small molecule degraders [3] - Founded in 2016, Kymera has been recognized as one of Boston's top workplaces in recent years [3] Communication and Information Availability - Kymera encourages investors and the public to review information posted on its website and social media platforms, which may contain material information [4] - The company utilizes its website for corporate disclosures, investor presentations, SEC filings, and press releases [4]